Amryt Pharma Share Discussion Threads

[chica1] 25/11/2019 12:43

Thanks👍
I don't know why Wenxin Wang is setting up a new company with his own team.

[papillon] 25/11/2019 12:42

chica1
25 Nov '19 - 12:24 - 5139 of 5140
0 0 0
There is nothing new there.That is what we knew back at the beginning of 2019.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

True, chica, but these trials take time to organise. It's mentioned in the RNS that it's a 3 year project. Anyway Amryt now have 2 revenue generating drugs on sale in the USA, Europe and elsewhere in the world. That revenue is evidently capable of significant growth so I presume Amryt's current focus is primarily on those 2 products and incorporating Aegerion into Amryt. Amryt has been transformed from a company with a tiny turnover into one with a circa US$150m worldwide turnover almost overnight. Patience is obviously required after such a dramatic change of direction.

PS My main gripe at the moment is not any delay in progressing AP101, or AP103, but the delay in announcing a date for the Nasdaq listing.

[papillon] 25/11/2019 12:27

chica, read the trading update RNS issued 3 weeks ago on the 5th November for the latest on AP101. No firm date for the Phase 111 trial results was given, just that all the patients will be "enrolled in the coming months".

"AP101 EASE study update:
o In January 2019, following an assessment of the results of an unblinded interim efficacy analysis of its pivotal Phase 3 EASE trial for AP101 as a potential treatment for the wound-related complications of Epidermolysis Bullosa ("EB"), the Independent Data Monitoring Committee (IDMC) recommended that the trial should continue with an increase of 48 patients in the study to a total of 230 evaluable patients, in order to maintain 80% statistical power. Amryt has currently enrolled 203 patients in the study and is on track to be fully enrolled in the coming months.
o Following an assessment in February 2019 by the EASE trial's IDMC of pharmacokinetic ("PK") data received from patients already enrolled in the trial (aged four years and older), Amryt is now enrolling infants and children with EB between the ages of 21 days to 4 years of age into the trial
o In October 2019, AP101 received Fast Track Designation from the FDA (Food and Drug Administration). Fast Track designation enables more frequent communication with the FDA and may allow for further benefit from FDA accelerated programmes such as priority review and/or rolling review."



Regarding AP103, that RNS issued 2 months ago, says that their are 3 partners in the "consortium". Amryt, UCD and DEBRA Ireland and that Amryt is the lead partner which must mean that Amryt has the largest stake in AP103, but what percentage that is isn't mentioned. 40%,50%, or 80%? We just don't know because we haven't been told!

[chica1] 25/11/2019 12:24

There is nothing new there.That is what we knew back at the beginning of 2019.

[chica1] 25/11/2019 11:32

I wonder what all this means for Amryt.I think February is the last time we have heard about AP103 from Amryt.Why aren't we in clinical trials?
I was reading over the weekend and I think AP101 is 1 1/2 behind schedule.

[papillon] 24/11/2019 13:18

I've copied these posts from another thread:

spuddymadrid
24 Nov '19 - 09:25 - 10 of 12
0 0 0
hxxps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/

spuddymadrid
24 Nov '19 - 09:28 - 11 of 12
0 0 0
2.) Branca Bunús is developing a technology to help cure Epidermolysis bullosa (EB) which affects half a million people worldwide.

EB is a devastating genetic disorder that makes the skin as fragile as butterfly wings and for which there is currently no cure. Branca Bunús is developing a technology which targets the ‘wrong’ part of the diseased skin cells to correct them and help cure the disease.

The Branca Bunús team includes, Professor Wenxin Wang, Dr Irene Lara Sáez, Dr Qian Xu, Dr Jonathan O’Keeffe Ahern, Dr Sigen A, UCD School of Medicine and Dr Hungyun Tai and Dr Dezhong Zhou.

papillon
24 Nov '19 - 13:10 - 12 of 12 Edit
0 0 0


I think you'll find that this UCD startup, Branca Bunus, is the gene therapy that AMYT have a stake in, spuddymadrid. It was stated previously that a new company would be set up to develop the novel gene therapy.



"The grant has been awarded to a consortium comprised of Amryt, University College Dublin ("UCD"), Curran Scientific Limited and DEBRA Ireland. The grant funding will be matched by the consortium partners at various funding levels over the three year term of the project".

[papillon] 24/11/2019 13:10

I think you'll find that this UCD startup, Branca Bunus, is the gene therapy that AMYT have a stake in, spuddymadrid. It was stated previously that a new company would be set up to develop the novel gene therapy.



"The grant has been awarded to a consortium comprised of Amryt, University College Dublin ("UCD"), Curran Scientific Limited and DEBRA Ireland. The grant funding will be matched by the consortium partners at various funding levels over the three year term of the project".

[spuddymadrid] 24/11/2019 09:28

2.) Branca Bunús is developing a technology to help cure Epidermolysis bullosa (EB) which affects half a million people worldwide.

EB is a devastating genetic disorder that makes the skin as fragile as butterfly wings and for which there is currently no cure. Branca Bunús is developing a technology which targets the ‘wrong’ part of the diseased skin cells to correct them and help cure the disease.

The Branca Bunús team includes, Professor Wenxin Wang, Dr Irene Lara Sáez, Dr Qian Xu, Dr Jonathan O’Keeffe Ahern, Dr Sigen A, UCD School of Medicine and Dr Hungyun Tai and Dr Dezhong Zhou.

[spuddymadrid] 24/11/2019 09:25

hxxps://www.engineersjournal.ie/2019/11/22/seven-emerging-startups-set-to-pitch-at-final-of-ucd-2019-accelerator-programme/

[papillon] 21/11/2019 12:19

Where's that Nasdaq listing date? The share price needs it.

[papillon] 15/11/2019 19:33

"Cheers & have a splendiforous weekend!!" And let me wish the same for you, bazworth.

I could do with an over £20k profit on my modest AMYT investment. Bring it on and the sooner the better! Will it happen? I can't predict share prices, but fingers crossed it does!

[bazworth] 15/11/2019 18:48

My eyes are firmly closed! Please text a voice message to me when we get there. My meagre stipend in retirement could do with a good shove!!

Cheers & have a splendiforous weekend!!

[papillon] 15/11/2019 18:34

Another two 25k trades, bazworth, both @ 118p reported after the market closed at 4:35pm. Probably reporting delayed by an hour since there was no after close auction announced. The 118p price dictates they were both sells, but they could have been a rollover because the time difference between the two trades was just 13 seconds.

Whatever they were that brings the number of trades today to 22.

"Just wait till we’re @ £5 a share!!" When will that be, bazworth? Next week, next month, next year? Have another look into your crystal ball, bazworth, as I need more clarity! Hopefully I don't have to wait too long for that £5 per share as I'm getting on a bit! :-)

[bazworth] 15/11/2019 17:23

Marvellous!!!

Just wait till we’re @ £5 a share!!

[papillon] 15/11/2019 16:49

I spoke too soon this morning! Some big volume trades this afternoon. 4 large trades totalling around 112k of shares. The biggest was for 35,650 @ 119.25p. It's shown as a sell because it's reporting was delayed by an hour. However when the trade took place (14:38:20) the quoted spread was 117p - 120p so it was a buy.

[bageo] 14/11/2019 21:44

It's a technicality - when considering valuation just include these shares as still being in issue.

They will be reissued for no money when it suits the funds - who can't hold the shares now without breaching limits. Hence no price for the buy back.

[chica1] 14/11/2019 17:15

Share buyback?
I don't understand,I don't see any price.

[papillon] 13/11/2019 16:01

O/T. Big drop in the ECO share price today following the RNS. Glad I no longer dabble in speculative AIM O&G's. I'm just gambling on an AIM listed speculative biotech, AMYT, instead!

[papillon] 11/11/2019 21:56

Two massive trades timed at just before 1pm, but only reported after the market closed. Both sells, but the share price responded by going up! I wonder if the trades have been worked over a number of days and have been depressing the share price and that now they have gone the share price will start to rise?

These are the two trades:

400,000 @ 115.625p and timed @ 12:55:07. Proceeds £462,500,000

474,135 @ 115.50p and timed @ 12:54:15. Proceeds £547,630,000

[papillon] 10/11/2019 18:03

Wiley in the right with Amryt
Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each.
Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive.
Wiley by name, wily by nature.

[e-mail]

[alphabravo321] 10/11/2019 17:19

Yep Sunday Times

[papillon] 10/11/2019 13:07

alphabravo321, you posted the following on the lse bb today. Does ST refer to the Sunday Times? tia

alphabravo321
Posts: 33
Price: 121.00
No Opinion
ST
Today 05:30
Wiley in the right with Amryt
Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each.

Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive.

Wiley by name, wily by nature.